Skip to main content
SpringerLink
Log in

Therapie des Nierenzellkarzinoms

Treatment of renal cell carcinoma

  • CME Weiterbildung • Zertifizierte Fortbildung
  • Published:
Der Onkologe Aims and scope

Zusammenfassung

Die Therapie des Nierenzellkarzinoms (NCC) hat sich in den letzten 5 Jahren einem raschen Wandel unterzogen. Eine kurative Behandlung stellt nach wie vor die chirurgische Therapie dar. Inzwischen haben Nephron sparende Eingriffe, die palliative Nephrektomie und Teilresektionen das chirurgische Repertoire erweitert. Die Systemtherapie des metastasierten NCC basiert seit den frühen 1980er Jahren auf dem Einsatz der Immuntherapie. Sunitinib und Sorafenib stellen seit 10 Jahren die ersten Neuzulassungen zur systemischen Therapie dar. Beide Medikamente zeigen eine außergewöhnliche klinische Aktivität und sind Vertreter der ersten Generation von Medikamenten einer neuen Therapieära des NCC. Daneben befinden sich weitere neue Substanzen in der klinischen Entwicklung. Der Einsatz dieser neuen Monotherapien und die Testung neuer Kombinationsregimes sind Gegenstand aktueller klinischer Forschung und helfen, die zukünftige Therapie des NCC vielfältig zu gestalten.

Abstract

Over the past 5 years, the treatment of renal cell carcinoma (RCC) has undergone a dramatic change. Surgery in the early disease stages is still the only known curative treatment modality, while palliative nephrectomy, nephron sparing surgery and partial resection have now enriched the surgical repertoire. During the early 1980s, immunotherapies remained the mainstay of systemic treatment of metastatic RCC. Sorafenib and sunitinib were the first new drugs to be approved for the treatment of advanced or metastatic RCC in the past 10 years. Both drugs show tremendous potency and provide novel future perspectives for drug treatment in RCC. Currently, the optimal combination of drugs is being explored in clinical studies and results are thought to elucidate the role of combined targeted therapies in RCC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Amato RJ (2005) Renal cell carcinoma: review of novel single-agent therapeutics and combination regimens. Ann Oncol 16: 7–15

    Article  PubMed  Google Scholar 

  2. Atkins MB, Hidalgo M, Stadler WM et al. (2004) Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22: 909–918

    Article  PubMed  Google Scholar 

  3. Atzpodien J, Kirchner H, Jonas U et al. (2004) Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a prospectively randomized trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J Clin Oncol 22: 1188–1194

    Article  PubMed  Google Scholar 

  4. Barkholt L, Bregni M, Remberger M et al. (2006) Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe. Ann Oncol 17: 1134–1140

    Article  PubMed  Google Scholar 

  5. Blom JH, Van Poppel H, Marechal JM et al. (1999) Radical nephrectomy with and without lymph node dissection: preliminary results of the EORTC randomized phase III protocol 30881. EORTC Genitourinary Group. Eur Urol 36: 570–575

    Article  PubMed  Google Scholar 

  6. Coppin C, Porzsolt F, Awa A et al. (2005) Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2005: CD001425

    Google Scholar 

  7. Eggener SE, Yossepowitch O, Pettus JA et al. (2006) Renal cell carcinoma recurrence after nephrectomy for localized disease: predicting survival from time of recurrence. J Clin Oncol 24: 3101-3106

    Google Scholar 

  8. Escudier B, Szczylik C, Eisen T et al. (2005) Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma (RCC). ASCO Annual Meeting Proceedings. J Clin Oncol 23: 4510

    Google Scholar 

  9. Ficarra V, Righetti R, Pilloni S et al. (2002) Prognostic factors in patients with renal cell carcinoma: retrospective analysis of 675 cases. Eur Urol 41: 190–198

    Article  PubMed  Google Scholar 

  10. Flanigan RC, Salmon SE, Blumenstein BA et al. (2001) Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 345: 1655–1659

    Article  PubMed  Google Scholar 

  11. Hudes G, Carducci M, Tomczak P et al. (2006) A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC). ASCO Annual Meeting Proceedings Part I. J Clin Oncol 24: LBA4

    Google Scholar 

  12. Huland E, Heinzer H, Timm S et al. (2002) [Immunotherapy of metastatic renal cell carcinoma in Germany. An assessment of the current status]. Urologe A 41: 282–287

    Article  PubMed  Google Scholar 

  13. Itano NB, Blute ML, Spotts B et al. (2000) Outcome of isolated renal cell carcinoma fossa recurrence after nephrectomy. J Urol 164: 322–325

    Article  PubMed  Google Scholar 

  14. Javidan J, Stricker HJ, Tamboli P et al. (1999) Prognostic significance of the 1997 TNM classification of renal cell carcinoma. J Urol 162: 1277–1281

    Article  PubMed  Google Scholar 

  15. Kavolius JP, Mastorakos DP, Pavlovich C et al. (1998) Resection of metastatic renal cell carcinoma. J Clin Oncol 16: 2261–2266

    Google Scholar 

  16. Lonser RR, Glenn GM, Walther M et al. (2003) von Hippel-Lindau disease. Lancet 361: 2059–2067

    Article  PubMed  Google Scholar 

  17. Lundstam S, Jonsson O, Lyrdal D et al. (2003) Nephron-sparing surgery for renal cell carcinoma – long-term results. Scand J Urol Nephrol 37: 299–304

    Article  PubMed  Google Scholar 

  18. Mickisch GH, Garin A, Van Poppel H et al. (2001) Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 358: 966–970

    Article  PubMed  Google Scholar 

  19. Motzer RJ, Bacik J, Murphy BA et al. (2002) Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20: 289–296

    Article  PubMed  Google Scholar 

  20. Motzer RJ, Hutson TE, Tomczak P et al. (2006) Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-α) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC). ASCO Annual Meeting Proceedings Part I. J Clin Oncol 24: LBA3

    Article  Google Scholar 

  21. Motzer RJ, Michaelson MD, Redman BG et al. (2006) Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24: 16–24

    Google Scholar 

  22. Motzer RJ, Rini BI, Bukowski RM et al. (2006) Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295: 2516–2524

    Article  PubMed  Google Scholar 

  23. Negrier S, Gomez F, Douillard JY et al. (2005) Prognostic factors of response or failure of treatment in patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d’Immunotherapie. World J Urol 23: 161–165

    Article  PubMed  Google Scholar 

  24. Novick AC (2004) Laparoscopic and partial nephrectomy. Clin Cancer Res 10: 6322S–6327S

    Article  PubMed  Google Scholar 

  25. Pantuck AJ, Zisman A, Dorey F et al. (2003) Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection. J Urol 169: 2076–2083

    Article  PubMed  Google Scholar 

  26. Pesch B, Haerting J, Ranft U et al. (2000) Occupational risk factors for renal cell carcinoma: agent-specific results from a case-control study in Germany. MURC Study Group. Multicenter urothelial and renal cancer study. Int J Epidemiol 29: 1014–1024

    Article  PubMed  Google Scholar 

  27. Piltz S, Meimarakis G, Wichmann MW et al. (2002) Long-term results after pulmonary resection of renal cell carcinoma metastases. Ann Thorac Surg 73: 1082–1087

    Article  PubMed  Google Scholar 

  28. Quesada JR, Swanson DA, Trindade A et al. (1983) Renal cell carcinoma: antitumor effects of leukocyte interferon. Cancer Res 43: 940–947

    PubMed  Google Scholar 

  29. Ratain MJ, Eisen T, Stadler WM et al. (2006) Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24: 2505–2512

    Google Scholar 

  30. Ravaud A, Audhuy B, Gomez F et al. (1998) Subcutaneous interleukin-2, interferon alfa-2a, and continuous infusion of fluorouracil in metastatic renal cell carcinoma: a multicenter phase II trial. Groupe Francais d’Immunotherapie. J Clin Oncol 16: 2728–2732

    PubMed  Google Scholar 

  31. Rini BI, Halabi S, Barrier R et al. (2006) Adoptive immunotherapy by allogeneic stem cell transplantation for metastatic renal cell carcinoma: a CALGB intergroup phase II study. Biol Blood Marrow Transplant 12: 778–785

    Article  PubMed  Google Scholar 

  32. Rosenberg SA, Lotze MT, Muul LM et al. (1985) Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313: 1485–1492

    PubMed  Google Scholar 

  33. Yang JC, Haworth L, Sherry RM et al. (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349: 427–434

    Article  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor weist auf eine Verbindung mit folgender Firma/Firmen hin: Referententätigkeit durch Fa. Pfizer zum NCC. Trotz des möglichen Interessenkonflikts ist der Beitrag unabhängig und produktneutral.

Author information

Authors and Affiliations

  1. Abteilung für Hämatologie, Hämostaseologie und Onkologie, Medizinische Hochschule Hannover, Carl-Neuberg-Straße 1, 30625 , Hannover

    V. Grünwald, C. Reuter, A. Ganser, S. Ehrlich & P. Ivanyi

Authors
  1. V. Grünwald
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Reuter
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Ganser
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S. Ehrlich
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P. Ivanyi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to V. Grünwald.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Grünwald, V., Reuter, C., Ganser, A. et al. Therapie des Nierenzellkarzinoms. Onkologe 12, 1153–1168 (2006). https://doi.org/10.1007/s00761-006-1142-3

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00761-006-1142-3

Schlüsselwörter

Keywords

Search

Navigation